Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Recruiting now · Not applicable

Conditions studied: Rectal Cancer, Rectal Tumor, Rectal/Anal

In brief

A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.

Key facts

Study ID

NCT04184973

Run by

Colospan Ltd.

People needed

250

Starts

2020-06-23

Expected to finish

2026-12-31

Last updated by the study team

2026-07-06

Who can join

Age: 22 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient is willing to comply with protocol-specified follow-up evaluations
• Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed.
• Patient is diagnosed with colorectal cancer
• Patient is scheduled for elective either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis, maximally 10 cm from the anal verge
• Patients who are scheduled to receive a protective stoma under routine clinical practice during their primary planned operation.
• Patient is scheduled to undergo mechanical bowel preparation
• The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).

You may not qualify if…

• Patient has local or systemic infection at the time of intervention (e.g., peritonitis)
• Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion).
• Patients with ASA classification > 3
• Albumin < 30 g/liter
• Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease
• Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression
• BMI ≥ 40
• Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery.
• The patient is currently participating in another investigational drug or device study unless pre-approved by the sponsor.
• Patient has been taking regular systemic/ steroid medication in the last 6 months.
• Patients is taking antimetabolites or antiplatelet agents.
• Patient has preexisting sphincter problems
• Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis.
• Patients with massive diverticulosis at the sigmoid/descending colon (viewed on preoperative CT)
• Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data
• Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.

Where it is running

• Soroka University Medical Center — Beersheba, Israel (enrolling)
• Humanitas Research Hospital — Milan, Lombardy, Italy (enrolling)
• CHUV — Lausanne, Switzerland (enrolling)
• Henry Ford Health System — Detroit, Michigan, United States (enrolling)
• Kaiser Permanente San Diego medical Center — San Diego, California, United States (enrolling)
• Colorado University Anschutz Medical Campus — Aurora, Colorado, United States (enrolling)
• Asklepios — Hamburg, Germany (enrolling)
• University of Utah Health — Salt Lake City, Utah, United States
• Lifespan & Brown Surgical Associates — Providence, Rhode Island, United States
• University of California Irvine — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.